THE ALCOVE TOOLBOX FOR ANTIPSYCHOTICS LIMITATION IN DEMENTIA

A WORLDWIDE SHARED SAFETY ISSUE



THE ALCOVE TOOLBOX FOR ANTIPSYCHOTICS LIMITATION IN DEMENTIA A wordwide shared safety issue

Dr Banaei-Bouchareb, Linda^a; Professor López-Peña Ordoñe, Tomás^b; Micheneau, Carole^a; Dr Villar Acevedo, Gloria^b; Arévalo Nieto, Gonzalo^b; Dr García García, Mercedes^b; Calvo Orra, Luis^b; María de la Rúa, José^b; Professor Segovia Pérez, Carlos^b; Dr Leperre Desplanques, Armelle^a

"Haute Autorité de Santé, France; ^bInstituto de Salud Carlos III, Spain

WHY SUCH A TOOLBOX?	85
THE WORLD HEALTH ORGANISATION POINT OF VIEW	85
ILLUSTRATIONS	86

ACKNOWLEDGEMENTS

THANKS TO THE ENTIRE ALCOVE EXECUTIVE BOARD FOR THEIR CONTRIBUTION TO THE ALCOVE TOOLBOX: Armelle Leperre-Desplanques, ALCOVE Project Leader, Nathalie Riolacci-Dhoyen, Haute Autorité de Santé, Work Package 1 - Carlos Segovia, Tomas Lopez Peña-Ordoñez, Instituto de Salud Carlos III, Work Package 2; Michal Novak, Rostislav Skrabana, Institute of Neuroimmunology, Work Package 3; Nicola Vanacore, Angela Giusti, Istituto Superiore di Sanità, Work Package 4; Dawn Brooker, Karim Saad, The Association for Dementia Studies, University of Worcester, Work Package 5; Harriet Finne-Soveri, Matti Mäkelä, Institute of Health and Welfare, Work Package 6; Gerrit Rauws, Bénédicte Gombault, King Baudouin Foundation, Work Package 7.

WE ALSO WISH TO THANK: Christine Barr, Nadia Chambers, Alistair Burns and Philippe Robert

ALL SURVEY RESPONDENTS: Stephen Abela, Anasthanase Bénétos, Jean-Christophe Bier, Jean-François Dartigues, Chantal Girtanner, Catherine Helmer, Thérèse Jonveaux, Esme D. Moniz-Cook, Katarina Nägga, Sakka Paraskevi, Eric Salmon

All the contents of the ALCOVE Toolbox are available on line: www.alcove-project.eu





WHY SUCH A TOOLBOX?

Overprescribing of antipsychotics for the behavioural disorders in dementia represents a major worldwide safety & ethical issue that has been underlined by the World Health Organisation [1]. It is well known today that chronic exposure to antipsychotics (AP) is non-effective and deleterious for people living with dementia as it can lead to falls, excessive sedation, stroke and an increased risk of mortality, with an overall profoundly negative impact on the individual's health, ability to communicate and quality of life.

The ALCOVE sustainable network has provided the opportunity to make a statement in Europe on the crucial issue of iatrogenicity and overuse of antipsychotics in dementia, underlined by the WHO and identified by the European Medicine Agency [2] as a priority research for 2013. In Europe, methods, references, tools and expertise are available in the field of safety & antipsychotics risk reduction. These successful experiences might be useful for those European countries wishing to promote risk reduction programmes.

To avoid deferring to other sedative drugs or physical restraints & to achieve improvements in outcome for people living with dementia, antipsychotics reduction in behavioural and psychological symptoms of dementia (BPSD) should be developed along with BPSD prevention and management improvement, using non pharmacological alternatives to antipsychotics and individualised patient and carer interventions, including psychosocial interventions.

ALCOVE European Member States have chosen to build a shared Toolbox to tackle the safety issue of limiting antipsychotics in dementia (Figure 1). This Toolbox provides concrete tools, key messages and experiences for all actors and in all dimensions of care: dedicated risk measurement (Figure 2) & risk reduction programmes (Figure 3), timely diagnosis, prevention & management of BPSD, and ethics in practice (Figure 4), all related to the use of antipsychotics.

WORLD HEALTH ORGANISATION POINT OF VIEW

Issues in the use of antipsychotic medication for people living with dementia, WHO, 2012 (1)

"There has been increasing concern about the use of antipsychotic drugs for the management of behavioural and psychological symptoms in dementia. These drugs appear to be used too often and, at their likely level of use, potential benefits risks may be more than the benefits. This is a problem across the world.

Although the first-line treatment for behavioural and psychological symptoms of dementia is non pharmacological, the prescription of psychotropic medication remains high and it appears that current systems deliver a largely antipsychotic-based response. These drugs appear to have only a limited positive effect in treating these symptoms but can cause significant harm to people with dementia. The risks include cerebrovascular adverse events and mortality. Clearly, some people benefit from these medications (e.g. where there is severe and complex risk). However, the current level of use of antipsychotics for people with dementia presents a significant issue in terms of quality of care, with negative impacts in patient safety, clinical effectiveness and the patient experience.

The mounting body of evidence documenting these risks has led North American and European regulatory authorities to issue warnings against the use of atypical antipsychotics to treat patients with dementia, and the US Food and Drug Administration now requires both atypical and typical antipsychotic drugs to carry a "black box" warning label highlighting the increased risk of mortality. Despite these warnings, antipsychotic drug use still seems to be widespread, particularly in care settings. Studies indicate that prescribing rates for antipsychotic medication use in dementia varies from 20% to 33% and most cases are residing in nursing homes. Less is known of the use of these medicines in the community and in acute hospital settings.

Evidence exists that, in many cases, difficult behaviour can be safely managed by use of psychosocial interventions or a personcentred care approach. Staff should receive training and guidance in delivering psychosocial interventions. Antipsychotics should be considered as an option only in cases of imminent risk of harm to self and other. If these drugs must be used, they should be prescribed in low doses over short periods and maintained only if benefits are apparent. Discontinuation should be attempted regularly."



ILLUSTRATIONS

Figure 1. The online ALCOVE TOOLBOX for antipsychotics limitation in Dementia: the Home page.




Figure 2. The online ALCOVE TOOLBOX for antipsychotics limitation in Dementia: Antipsychotics' Risk Measurement





Figure 3. The online ALCOVE TOOLBOX for antipsychotics limitation in Dementia: Antipsychotics' Risk Reduction Programmes

ANTIPSYCHOTICS' RISK REDUCTION **PROGRAMMES IN EUROPE** Different strategies have been implemented in Europe to limit the prescription of antipsychotics & then the risk of exposure in dementia. Risk reduction in Europe: Alcove surveys results European projects - The UK Call for Action Optimising treatment and care for behavioural and psychological symptoms of demential - The French AMI Alzheimer programme A best practice guide. Antipsychotic prescription, Safety monitoring guidance & Monitoring plan, Review guidance & Review chart http://www.alzheimers.org.uk/site/scripts/download_info.php?downloadID=609 Alert & Mastering Indicator for latrogenicity (AMI) Recommendations and Tools . Alert indicator: measures the risk "rate of people living with dementia exposed to for risk reduction long-term antipsychotics prescription" Mastering indicator: measures the management of the risk "rate of appropriate antipsychotics prescription (revised and argued)" • Medicines Management Tool for Antipsychotics. NHS 2013 http://www.hey.nhs.uk/content/files/prescribingCommittee/guidelines/antipsychotics.pdf • The Italian Legislation framework for Antipsychotics' Risk Reduction: a programme of active pharmacovigilance for antipsychotics prescription, and their role in the treatment of psychotic and behavioural disorders in persons living with dementia.

Figure 4. The online ALCOVE TOOLBOX for antipsychotics limitation in Dementia: Ethics in practice & Antipsychotics



REFERENCES

- World Health Organisation «Dementia, a public health priority ». 2012 http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdf
- European Medicines Agency. European Medicines Agency 2013 priorities for drug safety research. Long term safety effects of antipsychotics in patients with dementia. 2012 The online ALCOVE TOOLBOX www.alcove-project.eu